Comparison of postoperative radiotherapy versus postoperative paclitaxel and platinum chemotherapy in uterine endometrial carcinoma.
- Author:
Min Chul CHOI
1
;
Ji Hyeon PARK
;
Su Hyun KIM
;
Kyung Hun JUN
;
Sang Geun JUNG
;
Young Jeong NA
;
Sun Young LEE
;
Chan LEE
;
Yeun Young HWANG
;
Seung Jo KIM
Author Information
1. Comprehensive Gynecologic Cancer Center, Department of Obstetrtics and Gynecology, Bundang CHA General Hospital, College of Medicine, Pochon CHA University, Seongnam, Korea. ia0022@hanmail.net
- Publication Type:Original Article
- Keywords:
Uterine endometrial carcinoma;
Adjuvant chemotherapy;
Adjuvant radiotherapy
- MeSH:
Area Under Curve;
Carboplatin;
Chemotherapy, Adjuvant;
Cisplatin;
Disease-Free Survival;
Endometrial Neoplasms;
Female;
Follow-Up Studies;
Humans;
Paclitaxel;
Platinum;
Radiotherapy, Adjuvant
- From:Korean Journal of Obstetrics and Gynecology
2008;51(11):1280-1287
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study was performed to compare postoperative adjuvant paclitaxel and platinum (TC) chemotherapy and radiation therapy in women with uterine endometrial carcinoma. METHODS: Total one hundred five patients were entered into this trial. Non-endometrioid histologic subtypes such as serous, clear cell and small cell types were excluded from the study because they have different biological potentials. Of 58 assessable patients, who were needed adjuvant treatment according to surgico-pathologic reports, after surgery, 34 were received TC chemotherapy and 24 were received radiation therapy. Chemotherapy consisted of paclitaxel 175 mg/m2 and carboplatin AUC 5 (or cisplatin 50 mg/m2) every 3 weeks for 3 or 6 cycles. Irradiation dosage was 4,500~5,040 cGy in 28 fractions. RESULTS: In 58 evaluated patients, median follow-up time was 40.3 months (range 7~64 months). The 5-year overall survival and 5-year disease-free survival were 91.3% and 91.0% in 34 patients treated with TC chemotherapy, and 91.4% and 82.8% in 24 cases who treated with radiation therapy, however, there were no significant difference (P=0.646, P=0.129). The most common adverse effect of TC chemotherapy was hematologic toxicity, which was manageable conservatively. The serious gastrointestinal complication of radiotherapy was noted in 5 patients (20.8%), three of these patients were received another bowel surgery, such as ileo-cecal bypass, however, symptoms were persisted after surgery. CONCLUSIONS: These data suggest that postoperative adjuvant TC chemotherapy is a promising treatment which could be substituted for radiation therapy, with major activity and a acceptable toxicity profile for the treatment of uterine endometrial carcinoma.
